의약품
1. 2016 - 2020 (Therapeutic Areas)
| 중분류 | 개수 | |
| 1 | Oncology | 88 |
| 2 | Diagnostics | 69 |
| 3 | Ophthalmology | 41 |
| 4 | Infectious Disease | 31 |
| 5 | Muscoskeletal, Rheumatology, & Osteology | 28 |
| 6 | herbal | 25 |
| 7 | Cardiovascular/Metabolic | 22 |
| 8 | Quasi-drug | 22 |
| 9 | CNS | 22 |
| 10 | Dermatology | 17 |
| 11 | Respiratory & Immuno-inflammatory | 13 |
| 12 | Rare Diseases | 12 |
| 13 | Vaccine & Virology | 10 |
| 14 | Transplant | 10 |
| 15 | DMF | 9 |
| 16 | Neurology | 7 |
| 17 | Endocrinology & Metabolic Disease | 7 |
| 18 | Gastroenterology | 4 |
| 19 | Haematology | 4 |
| 20 | nutrology | 4 |
| 21 | Obstetrics/Gynaecology | 3 |
| 22 | Pain Management | 1 |
| 23 | Anti-infectives | 1 |
| 24 | Others | 192 |
| 총합 | 642 |
Indication or task other than 1~23 is classified as Others.
Others is excluded from the above diagram
2. 2016 - 2020 (By phase)
| 중분류 | 개수 | |
| 1 | R&D | 154 |
| 2 | NDA & BLA | 130 |
| 3 | Phase 1 IND | 73 |
| 4 | Phase 2 IND | 43 |
| 5 | Phase 3 IND | 20 |
| 6 | Pricing & Reimbursement | 18 |
| 7 | Pahase 1/2a IND | 14 |
| 8 | GMP | 9 |
| 9 | RMP/PMS | 5 |
| 10 | Phase 2/3 IND | 2 |
| 11 | IIT(Investigator Initiated Trial) IND | 2 |
| 12 | Others | 172 |
| 총합 | 642 |
Task other than 1~11 is classified as Others.